<DOC>
	<DOCNO>NCT00555282</DOCNO>
	<brief_summary>The use catheter associate infectious complication important iatrogenic source morbidity mortality . Certofix® protect catheter surface modify order reduce colonization bacteria . This clinical trial perform compare safety efficacy coat central venous catheter , Certofix® protect , non-coated standard catheter Certofix® .</brief_summary>
	<brief_title>Rate Catheter Colonization Risk Bloodstream Infection During Use Two Different Central Venous Catheters ( CVC )</brief_title>
	<detailed_description>Central venous catheter essential part patient management ICU ( Intensive Care Unit ) . The use catheter associate infectious complication important iatrogenic source morbidity mortality . Many catheter become colonized bacteria proportion colonise catheter go cause bacteriemia sepsis . It currently impossible prospectively identify catheter become colonized lead sepsis . Various type antiseptic antimicrobial vascular catheter coating develop . Studies show coated catheter effective limit catheter colonization rate may decrease risk catheter-related bloodstream infection . The `` Certofix protect '' develop B.Braun reduce risk catheter relate infection . It catheter modify surface consist high molecular weight polymer non-covalently link polyurethane catheter material . This clinical trial perform compare safety efficacy coat central venous catheter , Certofix® protect , non-coated standard catheter Certofix® .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<criteria>Patients probable ICU stay Patient 's first second catheter placement actual hospital stay Anticipated indwell central venous catheter period &gt; = 3 day ( jugular vein , subclavian vein ) &gt; = 18 year age Written inform consent patient independent physician prior participation ; case : write informed consent recovery possible The catheter place femoral vein Inflammation skin site puncture prior puncture Known hypersensitivity component ( i.e . polyhexanide related substance chlorhexidine ) Participation another clinical trial Emergency insertion catheter field</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>central venous catheter</keyword>
	<keyword>cvc</keyword>
	<keyword>coat catheter</keyword>
	<keyword>bacteriaemia</keyword>
	<keyword>bloodstream infection</keyword>
</DOC>